AliveCor, which is best known for its portable ECG devices, is launching Kardia Pro, touting it as an industry-first artificial intelligence-enabled platform for doctors to monitor patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia that leads to a five times greater risk of stroke.
“Kardia Pro tracks important measures of physiology like weight, activity and blood pressure, and, for the first time, AI technology is used to create a personal heart profile for each user, enabling user identification,” Vic Gundotra, AliveCor CEO, said in a statement. “The new platform enables doctors to be better doctors and patients to be more active participants in their own heart health, driving healthcare forward into the 21st century.”
AliveCor also announced a series D funding round of $30 million, led by Omron Healthcare, with participation from Mayo Clinic and existing inside investors. This investment will be used to help the company establish Kardia Pro as the new standard of care for doctors to enable early detection and prevention of heart disease and stroke. Also, some of the funds will be used to accelerate innovations in heart health and continue the rapid expansion of the business.
“Omron Healthcare is excited to expand our strategic partnership with AliveCor. We are establishing new partnerships to redefine the role of technology in heart health as part of our Going for Zero mission,” Omron Healthcare President and CEO Ranndy Kellogg said in a statement. “Partnering with AliveCor advances our path forward to build robust software programs that play a dynamic role in expanding heart health awareness, transforming the patient and caregiver dynamic and taking real steps toward eliminating heart attack and stroke.”